Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)
  7. Department of Pathology and Laboratory Medicine (416)
  8. Gastrointestinal Oncology Service (387)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Nosov, D.; Motzer, R. J.; Loewy, J.; Hodge, L.; Esteves, B.; Berkenblit, A.; Yin, W.; Dykstra, K.; Hutson, T. E.; Cotreau, M.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Novel circulating proteins, single nucleotide polymorphisms (SNPs), and molecular tumor markers as potential biomarkers of sunitinib efficacy in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Hutson, T. E.; Hudes, G. R.; Figlin, R. A.; Martini, J.; English, P. A.; Wood, L.; Huang, X.; Valota, O.; Williams, J. A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; Tomczak, P.; Negrier, S.; Gore, M. E.; Tarazi, J.; Hariharan, S.; Rosbrook, B.; Kim, S.; Rini, B. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Phase I trial of ASG-5ME in metastatic castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Morris, M.; Bruce, J.; Reyno, L.; Anand, B.; Hartford, A.; Jelaca-Maxwell, K.; Lackey, J.; Eisenberger, M.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • A phase IB clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Molina, A. M.; Hutson, T. E.; Larkin, J.; Gold, A.; Andresen, C.; Wood, K.; Motzer, R. J.; Michaelson, M. D.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study CA184-024
    Meeting Abstract

    Maio, M.; Bondarenko, I.; Robert, C.; Thomas, L.; Garbe, C.; Testori, A.; Francis, S.; Chin, K.; Wolchok, J.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials
    Meeting Abstract

    Lebbé, C.; Weber, J. S.; Maio, M.; Neyns, B.; Harmankaya, K.; Chin, K.; McDowell, D. O.; Cykowski, L.; McHenry, M. B.; Wolchok, J. D.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: Safety data by subgroups
    Meeting Abstract

    Lawrence, D.; McDermott, D. F.; Hamid, O.; Weber, J. S.; Wolchok, J. D.; Richards, J.; Amin, A.; Bennett, K.; Balogh, A.; Hodi, F. S.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers
    Meeting Abstract

    Kris, M.; Goldberg, Z.; Jänne, P. A.; Kim, D.; Martins, R.; Mok, T. S. K.; O'Connell, J.; Ou, S.; Taylor, I.; Zhang, H.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Brivanib (B) in advanced ovarian cancer (OC): Subset results of a phase 2 randomized discontinuation trial (RDT)
    Meeting Abstract

    Kaye, S. B.; Siu, L. L.; Jassem, J.; Medioni, J.; Soetekouw, Pmmb; Slater, S.; Rudin, C. M.; Schwartz, G. K.; De Jonge, M.; O'Dwyer, P.; more...
    Annals of Oncology (2012)

    Fulltext@MSK | Save